Prescribing Profile and Potential Drug Interactions in Tuberculosis Patients with Diabetes Mellitus Comorbidity at the Outpatient Pharmacy Installation of Hermina Podomoro Hospital

Bilah Samping Artikel

PDF (English)
Terbitan
Vol 3 No 2 (2026): Juli-Desember 2026
Diterbitkan: Nov 4, 2026

Isi Artikel Utama

Dini Permata Sari
Universitas 17 Agustus 1945 Jakarta, Indonesia

Abstrak

Tuberculosis (TB) remains a major public health problem in Indonesia, and diabetes mellitus (DM) comorbidity is associated with increased susceptibility to active TB and with the potential for clinically relevant interactions between anti-tuberculosis drugs (ATDs) and antidiabetic agents. Institution-specific data describing prescribing patterns and interaction risk among TB-DM patients remain limited, including at private hospitals such as Hermina Podomoro. This study aimed to describe the prescribing profile and potential drug interactions among TB-DM outpatients at Hermina Podomoro Hospital, and to examine the association between patient factors (sex, age, and number of concurrently prescribed drugs) and interaction severity. A descriptive-analytic study with a retrospective approach was conducted using medical records of 52 TB-DM outpatients selected through total sampling. Potential drug interactions were identified using the Medscape Drug Interaction Checker and Drugs.com, and associations were examined using the chi-square test (p < 0.05). All patients had at least one potential ATD-antidiabetic interaction, predominantly of moderate severity (76.9%), with no major interactions identified; the most frequent combination was an ATD with a sulfonylurea (25.0%). The number of concurrently prescribed drugs was significantly associated with interaction severity (p = 0.003), whereas sex (p = 0.417) and age (p = 0.239) were not. These findings suggest that, in this population, interaction risk may be more closely related to regimen complexity than to demographic factors; however, the retrospective, single-center design limits generalizability, and the findings should be interpreted with appropriate caution. Routine pharmacist-led medication review is recommended to support safe TB-DM pharmacotherapy.

Rincian Artikel

Cara Mengutip
Permata Sari, D. (2026). Prescribing Profile and Potential Drug Interactions in Tuberculosis Patients with Diabetes Mellitus Comorbidity at the Outpatient Pharmacy Installation of Hermina Podomoro Hospital. Medical : Jurnal Kesehatan Dan Kedokteran, 3(2), 353–361. https://doi.org/10.69836/medical-jkk.v3i2.1009
Bagian
Bagian Kebijakan
Creative Commons License

Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.

Referensi

Abbas, A. “Hubungan antara Diabetes Melitus dengan Kejadian Tuberkulosis Paru di Kota Kediri.” Jurnal Kesehatan Nusantara 11, no. 2 (2022): 120–128.

Abdullah, D., et al. “Adverse Drug Interactions among TB–DM Comorbid Patients in Malaysia: A Retrospective Evaluation.” Journal of Public Health Research 10, no. 3 (2024): 1896–1905.

Afrianti, R., R. Rahmadini, and N. Fadhilah. “Analisis Potensi Interaksi Obat pada Pasien Tuberkulosis dengan Komorbid Diabetes Melitus di Rumah Sakit Umum Pusat Dr. M. Djamil Padang.” Jurnal Farmasi Klinik Indonesia 8, no. 2 (2023): 104–112.

Al-Bari, M. A. A., M. T. Rahman, and M. R. Amin. “The Bidirectional Relationship of Tuberculosis and Diabetes Mellitus: Pathophysiological Insights and Clinical Outcomes.” Frontiers in Pharmacology 13 (2024): 883483. https://doi.org/10.3389/fphar.2022.883483.

Ambar Wati, N., S. Rahayu, and I. Putra. “Faktor Risiko dan Gambaran Klinis Pasien TB Paru dengan Komorbid Diabetes Melitus di RSU Dr. Soetomo Surabaya.” Jurnal Ilmu Kesehatan Masyarakat 14, no. 1 (2024): 45–53.

Andalusia, M., and I. Rahman. “Clinical Outcomes and Pharmacological Challenges of Tuberculosis–Diabetes Comorbidity.” Frontiers in Pharmacology 13 (2024): 876955. https://doi.org/10.3389/fphar.2022.876955.

Andalusia, M., and M. Sakundarno. “Hubungan Diabetes Melitus terhadap Luas Lesi dan Konversi Sputum pada Pasien TB Paru di Semarang.” Jurnal Kedokteran Tropis Indonesia 9, no. 1 (2023): 34–42.

Atikah, N., and S. Ronoatmodjo. “Faktor Risiko Kejadian Tuberkulosis Paru pada Penderita Diabetes Melitus di RS Fatmawati Jakarta.” Jurnal Epidemiologi Indonesia 3, no. 2 (2024): 55–63.

Auliafendri, F., et al. “Evaluation of Potential Drug–Drug Interactions among Tuberculosis and Diabetes Mellitus Patients in Indonesia Using Medscape Drug Checker.” PLOS ONE 19, no. 4 (2024): e0292397. https://doi.org/10.1371/journal.pone.0292397.

Azzahra, R. “Tingkat Kepatuhan Penggunaan OAT pada Pasien TB Paru dengan Komorbid DM di RSUD Arifin Achmad Pekanbaru.” Jurnal Farmasi Klinik dan Komunitas 11, no. 1 (2023): 28–36.

Azzahra, S., et al. “Hubungan Tingkat Kepatuhan Minum Obat terhadap Keberhasilan Pengobatan Pasien Tuberkulosis dengan Komorbid DM di RSUD Arifin Achmad Pekanbaru.” Jurnal Penelitian Kesehatan 12, no. 3 (2023): 211–222.

Desy, N., et al. “Potensi Interaksi Obat pada Pasien Tuberkulosis Paru di RSUD Dr. M. Soewandhie Surabaya.” Jurnal Farmasi dan Sains Indonesia 9, no. 2 (2023): 104–112.

Djochie, A. D., R. Ramadhani, and E. Lestari. “Polifarmasi dan Interaksi Obat pada Pasien Tuberkulosis dengan Komorbid Diabetes Melitus di RS Dr. Kariadi Semarang.” Jurnal Ilmiah Farmasi Klinis 8, no. 1 (2023): 15–23.

Gotera, W., R. J. Prasetya, and A. Anwar. “Hubungan antara Diabetes Melitus dengan Kejadian Tuberkulosis Paru: Kajian Epidemiologis dan Patogenesis.” Jurnal Respirasi Indonesia 41, no. 3 (2021): 176–182.

Handari, P. R., and S. Ronoatmodjo. “Faktor Risiko Efek Samping OAT pada Pasien Tuberkulosis dengan Komorbid Diabetes Melitus di RSUD Kota Bekasi.” Jurnal Epidemiologi Kesehatan 6, no. 1 (2024): 77–85.

International Conference on Clinical Medicine and Science (ICCMS). “Profil Peresepan dan Rasionalitas Penggunaan Obat pada Pasien TB Paru dengan Komorbid DM di Instalasi Rawat Jalan.” International Conference on Clinical Medicine and Science 5, no. 1 (2025): 139–146.

Islamiyah, N., et al. “Evaluasi Rasionalitas Penggunaan Obat Antituberkulosis pada Pasien Tuberkulosis Paru di Rumah Sakit Islam Surabaya.” Jurnal Farmasi dan Kesehatan 9, no. 1 (2024): 45–54.

Khan, M. T., M. N. Islam, and M. Y. Ali. “Adverse Effects and Treatment Outcomes in Multidrug-Resistant Tuberculosis Patients in Bangladesh.” World Journal of Diabetes 15, no. 6 (2022): 853–862. https://doi.org/10.4239/wjd.v15.i6.853.

Kurbatova, E. V., et al. “Efficacy and Safety of Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.” Clinical Infectious Diseases, advance online publication, 2025.

Medicina. “Pharmacokinetic Considerations in Tuberculosis–Diabetes Comorbidity and the Role of Clinical Pharmacists.” Medicina 61, no. 9 (2025): 911.

Medicine International. “Diabetes Mellitus and Tuberculosis: An Immunopathological Interplay and Clinical Management Perspective.” Medicine International 4, no. 1 (2024): 128–136.

Mereškevičienė, A., and E. Danila. “Adverse Drug Reactions in Tuberculosis Treatment: A Retrospective Study.” Medicina 61, no. 9 (2025): 911. https://doi.org/10.3390/medicina6100911.

Nadillah, R., S. Yuliani, and A. Pratama. “Hubungan Efek Samping OAT terhadap Kepatuhan Pasien Tuberkulosis dengan Komorbid Diabetes Melitus di RSUD Banyuwangi.” Jurnal Kesehatan Indonesia 14, no. 2 (2023): 97–105.

PLOS ONE. “Drug Interaction Profiles between Antituberculosis and Antidiabetic Medications among Hospitalized Patients.” PLOS ONE 18, no. 3 (2023): e0269765.

Ruben, F., S. Dini, and D. Yulita. “Kepatuhan Pengobatan dan Hasil Terapi pada Pasien TB–DM di RSUD Abdul Wahab Sjahranie Samarinda.” Jurnal Ilmu Kedokteran 17, no. 1 (2023): 30–39.

Ugarte-Gil, C., et al. “The TANDEM Study: Tuberculosis and Diabetes Mellitus Comorbidity in Four Countries.” The Lancet Global Health 8, no. 12 (2020): e1422–e1430.

Wahyudin, M., and P. Meyshella. “Prevalensi dan Faktor Risiko Tuberkulosis Paru di Indonesia Tahun 2024.” Jurnal Kesehatan Masyarakat Nasional 9, no. 2 (2024): 920–929.

World Health Organization. Global Tuberculosis Report 2024. Geneva: World Health Organization, 2024.